Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Naftifine is a synthetic, broad-spectrum antifungal agent of the allylamine class used topically to treat fungal skin infections such as tinea pedis (athlete's foot), tinea cruris (jock itch), and tinea corporis (ringworm) caused by dermatophytes including *Trichophyton rubrum*, *Trichophyton mentagrophytes*, *Trichophyton tonsurans*, and *Epidermophyton floccosum*. It was invented at the Sandoz Research Institute in Vienna and was the first successful antifungal medication of its class. Naftifine acts primarily by inhibiting squalene monooxygenase (squalene 2,3-epoxidase), an enzyme involved in sterol biosynthesis. This inhibition leads to decreased ergosterol production—an essential component of fungal cell membranes—and accumulation of squalene within fungal cells. The drug exhibits fungicidal activity against dermatophytes and molds and fungistatic activity against yeasts; it also has antibacterial and anti-inflammatory properties[3][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on naftifine.